These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7831443)

  • 41. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Current concepts of the effects of neuroleptics].
    Kostowski W; Płaźnik A
    Psychiatr Pol; 1990; 24(5):28-37. PubMed ID: 1983397
    [No Abstract]   [Full Text] [Related]  

  • 43. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential.
    Greenshaw AJ
    Trends Pharmacol Sci; 1993 Jul; 14(7):265-70. PubMed ID: 8105596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Possibility of 5-HT3 receptor involvement in alcohol dependence: a microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption.
    Yoshimoto K; Yayama K; Sorimachi Y; Tani J; Ogata M; Nishimura A; Yoshida T; Ueda S; Komura S
    Alcohol Clin Exp Res; 1996 Dec; 20(9 Suppl):311A-319A. PubMed ID: 8986229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
    Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors.
    Alhaider AA; Hamon M; Wilcox GL
    Eur J Pharmacol; 1993 Nov; 249(2):151-60. PubMed ID: 7507056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats.
    Iusco G; Boido V; Sparatore F; Colombo G; Saba PL; Rossetti Z; Vaccari A
    Farmaco; 1997 Mar; 52(3):141-6. PubMed ID: 9212448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The central serotonin
    Devroye C; Cathala A; Piazza PV; Spampinato U
    Pharmacol Ther; 2018 Jan; 181():143-155. PubMed ID: 28757154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of 5-hydroxytryptamine and dopamine neurones in the behavioural effects of alpha-methylytryptamine.
    Marsden CA
    Neuropharmacology; 1980 Aug; 19(8):691-8. PubMed ID: 6448356
    [No Abstract]   [Full Text] [Related]  

  • 52. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group.
    Nocjar C; Roth BL; Pehek EA
    Neuroscience; 2002; 111(1):163-76. PubMed ID: 11955720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology of schizophrenia and the role of newer antipsychotics.
    Risch SC
    Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions.
    White FJ
    Pharmacol Biochem Behav; 1986 Feb; 24(2):365-79. PubMed ID: 3952127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Influence of the selective ligands of dopamine and 5-hydroxytryptamine receptors on the tolerance to global cerebral ischemia].
    Kulinskiĭ VI; Gavrilov SS
    Eksp Klin Farmakol; 2006; 69(6):20-3. PubMed ID: 17209458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.